| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| 25mg | |||
| Other Sizes |
| Targets |
Corin targets two epigenetic enzymes: LSD1 (histone lysine-specific demethylase) and HDAC1 (histone deacetylase 1). By inhibiting both enzymes, Corin modulates histone methylation and acetylation, two key post-translational modifications that regulate chromatin structure and gene expression.
|
|---|---|
| ln Vitro |
Through the CoREST ternary complex, corin prevents semisynthetic, recombinant nucleosomes from being deacetylated. HDAC1 activity is irreversibly inhibited by corin. Corin seems to be more potent than MS-275 (EC50 of 95 nM against EC50 of 420 nM for MS-275) and causes cellular H3K9 necking more successfully. It's interesting to note that, in contrast to MS-275 (1 μM), Corin (1 μM) is not harmful to primary human melanocytes[1].
In vitro, Corin induces cellular H3K9 acetylation with an EC₅0 of 95 nM. The compound is non-toxic to primary human melanocytes. Through the CoREST ternary complex, Corin prevents semisynthetic recombinant nucleosomes from being deacetylated. |
| ln Vivo |
In vivo data for Corin are limited. As a dual LSD1/HDAC inhibitor, the compound is expected to have anti-cancer activity through epigenetic modulation. The compound is a valuable tool for studying coordinated LSD1/HDAC1 regulation, chromatin remodeling, and epigenetic cancer therapeutics.
|
| Enzyme Assay |
For in vitro enzyme binding assays, Corin is evaluated using recombinant LSD1 and HDAC1 enzymes. For LSD1, the compound is incubated with the enzyme and a histone H3 peptide substrate, and demethylase activity is measured. For HDAC1, the compound is incubated with the enzyme and a fluorogenic substrate, and deacetylase activity is measured. Ki(inact) and IC₅0 values are calculated.
|
| Cell Assay |
For in vitro cellular assays, Corin is dissolved in DMSO and applied to cancer cell lines. Histone H3K9 acetylation and H3K4 demethylation are assessed using Western blotting with specific antibodies. Cell proliferation, apoptosis, and gene expression changes are also evaluated.
|
| Animal Protocol |
In vivo animal studies with Corin typically involve oral or intraperitoneal administration in mouse xenograft models of cancer. Tumor growth inhibition, histone modification changes in tumor tissues, and tolerability are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Corin are limited. The compound has a molecular weight of 428.53 and molecular formula C2₆H2₈N4O2. It should be stored according to the conditions specified in the certificate of analysis.
|
| Toxicity/Toxicokinetics |
Toxicology data indicate that Corin is non-toxic to primary human melanocytes in vitro. As a dual epigenetic inhibitor, the compound may have broad effects on gene expression; careful dose optimization is required. Not approved for human use.
|
| References | |
| Additional Infomation |
Corin is a dual inhibitor of histone lysine-specific demethylase (LSD1) and histone deacetylase (HDAC), with a Ki(inact) of 110 nM for LSD1 and an IC50 of 147 nM for HDAC1.
Corin (CAS#: 1808113-09-8) has the molecular formula C2₆H2₈N4O2 and molecular weight 428.53. The chemical name is 4-[3-({4-[(1S,2R)-2-aminocyclopropyl]phenyl}carbamoyl)propyl]-N-(2-aminophenyl)benzamide. It is a research reagent only. |
| Molecular Formula |
C26H28N4O2
|
|---|---|
| Molecular Weight |
428.526125907898
|
| Exact Mass |
428.221
|
| CAS # |
1808113-09-8
|
| PubChem CID |
134828251
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
2.8
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
32
|
| Complexity |
625
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O=C(CCCC1C=CC(C(NC2C=CC=CC=2N)=O)=CC=1)NC1C=CC(=CC=1)C1CC1N
|
| InChi Key |
TYTLARZOLKJSJU-JTHBVZDNSA-N
|
| InChi Code |
InChI=1S/C26H28N4O2/c27-22-5-1-2-6-24(22)30-26(32)19-10-8-17(9-11-19)4-3-7-25(31)29-20-14-12-18(13-15-20)21-16-23(21)28/h1-2,5-6,8-15,21,23H,3-4,7,16,27-28H2,(H,29,31)(H,30,32)/t21-,23+/m0/s1
|
| Chemical Name |
4-[4-[4-[(1S,2R)-2-aminocyclopropyl]anilino]-4-oxobutyl]-N-(2-aminophenyl)benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~233.36 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3336 mL | 11.6678 mL | 23.3356 mL | |
| 5 mM | 0.4667 mL | 2.3336 mL | 4.6671 mL | |
| 10 mM | 0.2334 mL | 1.1668 mL | 2.3336 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
